Dermapharm Holding SE (DMPG)

Currency in EUR
39.60
-0.35(-0.88%)
Closed·
Earnings results expected in 10 days
DMPG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
38.9539.85
52 wk Range
31.7051.90
Key Statistics
Prev. Close
39.6
Open
39.85
Day's Range
38.95-39.85
52 wk Range
31.7-51.9
Volume
25.5K
Average Volume (3m)
21.28K
1-Year Change
20.1821%
Book Value / Share
13.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DMPG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
50.38
Upside
+27.21%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Dermapharm Holding SE News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 50.38
(+27.21% Upside)

Earnings

Latest Release
May 13, 2026
EPS / Forecast
0.84 / --
Revenue / Forecast
305.8M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.68%
Dividend Yield
2.20%
Industry Median 2.29%
Annualized payout
0.88
Paid unevenly
5-Years Growth
-
Growth Streak

DMPG Income Statement

Compare DMPG to Peers and Sector

Metrics to compare
DMPG
Peers
Sector
Relationship
P/E Ratio
13.6x19.1x−0.4x
PEG Ratio
0.35−0.260.00
Price/Book
2.7x2.7x2.6x
Price / LTM Sales
1.7x2.0x3.1x
Upside (Analyst Target)
23.1%15.0%47.8%
Fair Value Upside
Unlock13.4%6.2%Unlock

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

Employees
3503
Market
Germany

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.18M5.90%127.30M
Other Institutional Investors
43.94M81.62%1.76B
Public Companies & Retail Investors
6.72M12.48%269.10M
Total
53.84M100.00%2.16B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Themis Beteiligungs-AG79.50%42,801,0001,714,180
Mawer Investment Management Ltd.2.97%1,599,72864,069

People Also Watch

41.980
JENGn
+0.48%
31.000
TPEG
-1.65%
73.45
DWSG
-0.54%
24.880
JUNG_p
-0.32%
20.850
F3CG
0.00%

FAQ

What Is the Dermapharm (DMPG) Stock Price Today?

The Dermapharm stock price today is 39.60 EUR.

What Stock Exchange Does Dermapharm Trade On?

Dermapharm is listed and trades on the Frankfurt Stock Exchange.

What Is the Stock Symbol for Dermapharm?

The stock symbol for Dermapharm is "DMPG."

Does Dermapharm Pay Dividends? What’s The Current Dividend Yield?

The Dermapharm dividend yield is 2.2%.

What Is the Dermapharm Market Cap?

As of today, Dermapharm market cap is 1.96B EUR.

What Is Dermapharm's Earnings Per Share (TTM)?

The Dermapharm EPS (TTM) is 2.68.

When Is the Next Dermapharm Earnings Date?

Dermapharm will release its next earnings report on Aug 25, 2026.

From a Technical Analysis Perspective, Is DMPG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Dermapharm Stock Split?

Dermapharm has split 0 times.

How Many Employees Does Dermapharm Have?

Dermapharm has 3503 employees.

What is the current trading status of Dermapharm (DMPG)?

As of Aug 15, 2026, Dermapharm (DMPG) is trading at a price of 39.60 EUR, with a previous close of 39.60 EUR. The stock has fluctuated within a day range of 38.95 EUR to 39.85 EUR, while its 52-week range spans from 31.70 EUR to 51.90 EUR.

What Is Dermapharm (DMPG) Price Target According to Analysts?

The average 12-month price target for Dermapharm is 50.38 EUR, with a high estimate of 60 EUR and a low estimate of 44 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +27.21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.